In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies, and there is insufficient evidence regarding potential harm to humans
Reimar Thomsen, a professor of metabolic disease epidemiology at Aarhus University Hospital in Denmark, said in a news release
How It Works at MediSlim Book a paid consultation
Driven by quality excellence and customer-centric manufacturing solutions, we serve domestic and international markets with reliable, scalable, and regulatory-compliant pharmaceutical products
NAD+ has hundreds
Its preservative effect allows multiple withdrawals from the same vial, distinguishing it from sterile water for injection, which lacks preservatives and is intended for single use